Mechanisms Involved in the Protective Effects of Metformin Against Nonalcoholic Fatty Liver Disease

被引：3
作者：
Barbero-Becerra, V. J. [1 ]
Santiago-Hernandez, J. J. [1 ]
Villegas-Lopez, F. A. [1 ]
Mendez-Sanchez, N. [1 ]
Uribe, M. [1 ]
Chavez-Tapia, N. C. [1 ]
机构：
[1] Medica Sur Clin & Fdn, Obes & Digest Dis Unit, Mexico City 14050, DF, Mexico
来源：
CURRENT MEDICINAL CHEMISTRY | 2012年 / 19卷 / 18期
关键词：
Biguanides; insulin resistance; liver diseases; metabolic syndrome; metabolism; obesity; HEPATIC GLUCONEOGENESIS; VITAMIN-E; AMPK; EXPRESSION; DIET; STEATOSIS; PATHWAY; INJURY; TRIAL; OBESE;
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Metformin is an antidiabetic drug used widely in clinical practice. Its main clinical effect is to reduce blood glucose levels by improving insulin resistance. Nonalcoholic fatty liver disease is characterized by chronic liver damage and can develop into liver cirrhosis. Nonalcoholic fatty liver disease is associated with obesity and contributes to insulin resistance, and metformin is used to treat individuals with these conditions. The mechanisms underlying the clinical effects of metformin in treating nonalcoholic fatty liver disease are unclear. This article summarizes the literature on the mechanisms associated with liver glucose metabolism and the beneficial effects of metformin on this common liver disease.
引用
收藏
页码：2918 / 2923
页数：6
相关论文
共 45 条
  • [1] Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase
    Algire, Carolyn
    Amrein, Lilian
    Zakikhani, Mahvash
    Panasci, Lawrence
    Pollak, Michael
    [J]. ENDOCRINE-RELATED CANCER, 2010, 17 (02) : 351 - 360
  • [2] Metformin for aging and cancer prevention
    Anisimov, Vladimir N.
    [J]. AGING-US, 2010, 2 (11): : 760 - 774
  • [3] Arkad'eva A V, 2011, Tsitologiia, V53, P166
  • [4] Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1
    Bergheim, Ina
    Guo, Luping
    Davis, Molly Anne
    Lambert, Jason C.
    Beier, Juliane I.
    Duveau, Ilinca
    Luyendyk, James P.
    Roth, Robert A.
    Arteel, Gavin E.
    [J]. GASTROENTEROLOGY, 2006, 130 (07) : 2099 - 2112
  • [5] Genetic downregulation of AMPK-α isoforms uncovers the mechanism by which metformin decreases FA uptake and oxidation in skeletal muscle cells
    Bogachus, Lindsey D.
    Turcotte, Lorraine P.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2010, 299 (06): : C1549 - C1561
  • [6] Biguanides and thiazolidinediones inhibit stimulated lipolysis in human adipocytes through activation of AMP-activated protein kinase
    Bourron, O.
    Daval, M.
    Hainault, I.
    Hajduch, E.
    Servant, J. M.
    Gautier, J. F.
    Ferre, P.
    Foufelle, F.
    [J]. DIABETOLOGIA, 2010, 53 (04) : 768 - 778
  • [7] A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease
    Bugianesi, E
    Gentilcore, E
    Manini, R
    Natale, S
    Vanni, E
    Villanova, N
    David, E
    Rizzetto, M
    Marchesini, G
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (05) : 1082 - 1090
  • [8] Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5
    Caton, Paul W.
    Nayuni, Nanda K.
    Kieswich, Julius
    Khan, Noorafza Q.
    Yaqoob, Muhammed M.
    Corder, Roger
    [J]. JOURNAL OF ENDOCRINOLOGY, 2010, 205 (01) : 97 - 106
  • [9] Understanding the benefit of metformin use in cancer treatment
    Dowling, Ryan J. O.
    Goodwin, Pamela J.
    Stambolic, Vuk
    [J]. BMC MEDICINE, 2011, 9
  • [10] Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions
    Duseja, Ajay
    Das, Ashim
    Dhiman, Radha Krishan
    Chawla, Yogesh Kumar
    Thumburu, Kiran K.
    Bhadada, Sanjay
    Bhansali, Anil
    [J]. ANNALS OF HEPATOLOGY, 2007, 6 (04) : 222 - 226
12345